Varenicline For Vaping Cessation In Non Smoker Vaper Adolescents
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
The Investigators propose a randomized, placebo-controlled trial to test the hypothesis that
varenicline added to group behavioral and texting support will be well tolerated and improve
vaping cessation rates over behavioral treatment alone in nicotine-dependent adolescents who
vape, do not smoke, and want to quit. To do so, the investigators propose to enroll 300
adolescents in Greater Boston meeting these criteria in a double-blind, placebo-controlled,
parallel group, study of varenicline up to 1 mg bid for 12 weeks added to 12 weeks of group
behavioral and texting support specifically designed for teen vaping cessation.